Diridavumab |
| Katalog-Nr.GC72450 |
Diridavumab is a monoclonal anti-HA stalk antibody.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1393659-46-5
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Diridavumab (CR6261; 500 μg/mL) neutralized AA60 and Sw06 with 39.4 μg/mL and 176.8μg/mL, respectively[1].
Diridavumab (CR6261; 1.7-15 mg/kg; i.p.; BALB/c mice with H2 influenza virus) protects mice against lethal H2 influenza virus in a dose-dependent manner[1].
References:
[1]. Sutton TC, et, al. In Vitro Neutralization Is Not Predictive of Prophylactic Efficacy of Broadly Neutralizing Monoclonal Antibodies CR6261 and CR9114 against Lethal H2 Influenza Virus Challenge in Mice. J Virol. 2017 Nov 30;91(24):e01603-17.
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *